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Abstract
Strontium ranelate is one of the first-line agents with proven anti-fracture activity used in the therapy of post-menopausal osteoporosis.
Its mechanism of action makes it, however, different from other drugs, since it simultaneously stimulates two reverse processes: bone
formation and bone resorption. The action of the agent depends on various mechanisms, including the activation of calcium receptors,
localised on osteoblasts and osteoclasts, and on the influence on the OPG/RANKL system. The drug effectively prevents spinal, hip and
extravertebral fractures. The agent’s anti-fracture efficacy within the spine does not depend on the patient’s age, or on base BMD values,
or on the concentration of bone metabolism markers. As to the anti-fracture efficacy in the hip, it concerns women with an increased bone
fracture risk. Strontium ranelate increases bone mineral density within the lumbar spine and the hip, decreases the concentrations of bone
resorption markers, and increases the concentrations of bone formation markers. The drug is administered in a daily 2.0 g oral dose.
This paper presents indications to therapy with strontium ranelate, specifying also its side effects and contraindications. We compare the
anti-fracture efficacy of strontium ranelate to the efficacy of other agents of proven anti-fracture activity, based on published clinical
studies. (Pol J Endocrinol 2011; 62 (1): 65–72)
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Streszczenie
Ranelinian strontu jest lekiem pierwszego rzutu o udowodnionej aktywności przeciwzłamaniowej w leczeniu osteoporozy pomenopau-
zalnej. Mechanizm działania wyróżnia go spośród innych leków, wpływa bowiem jednocześnie na pobudzenie tworzenia i hamowanie
resorpcji kości. Działanie leku zależy od różnych mechanizmów, w tym od aktywacji receptorów wapniowych zlokalizowanych na oste-
oblastach i osteoklastach i wpływu na system OPG/RANKL. Lek jest skuteczny w zapobieganiu złamaniom kręgosłupa, biodra i złama-
niom pozakręgowym. Skuteczność przeciwzłamaniowa w zakresie kręgosłupa nie zależy od wieku pacjentów, wyjściowych wartości
gęstości mineralnej kości oraz stężenia markerów metabolizmu kostnego. Skuteczność przeciwzłamaniowa w zakresie biodra dotyczy
kobiet o zwiększonym ryzyku złamania kości. Ranelinian strontu zwiększa gęstość mineralną kości w zakresie kręgosłupa lędźwiowego
i biodra, obniża stężenie markerów resorpcji kości i podwyższa stężenie markerów tworzenia kości. Lek podaje się w codziennej dawce
2,0 doustnie. W opracowaniu omówiono wskazania do leczenia ranelinianem strontu, przeciwwskazania, działanie niepożądane leku,
a także porównano jego skuteczność do innych leków o udowodnionej aktywności przeciwzłamaniowej na podstawie przeprowadzo-
nych badań klinicznych. (Endokrynol Pol 2011; 62 (1): 65–72)
Słowa kluczowe: leczenie, osteoporoza, ranelinian strontu
Introduction
Strontium ranelate is a medical agent of proven anti-frac-
ture effectiveness which is used in the therapy of post-
menopausal osteoporosis as a first-line drug. The long-
est observation of the drug’s efficacy has been eight years.
Strontium ranelate structure
and mechanism of action
Strontium ranelate consists of an organic part (ranelic
acid) and two atoms of stable, non-radioactive stron-
tium. It is the only drug used in osteoporosis therapy
which demonstrates a dual mode of action towards bone
metabolism: it supports bone formation (osteogenesis),
stimulating the division of osteoblast precursor and col-
lagen synthesis, as well as the synthesis of non-collagen
proteins in osteoblasts, while simultaneously decreasing
bone resorption by inhibiting the activity and differen-
tiation of osteoclasts.
Several reports have been published looking at the
various mechanisms of strontium ranelate activity.
Calcium receptor
In studies on animals, a positive effect of strontium rane-
late has been noted on the proliferation, differentiation
and mineralisation of osteoblasts by activation of calcium
receptors on their surface, that effect being proportional
to the therapy period and the dose of the administered
drug [1, 2]. Strontium ranelate stimulates phosphoryla-
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tion and, consequently, the activation of intracellular
kinase of mouse osteoblasts (ERK, extracellular signal-
regulated kinase), and also increases the expression of
osteocalcin mRNA and bone morphogenetic protein-2.
In another study, also on animals, strontium rane-
late was observed on cells of mature osteoblasts to ac-
celerate their apoptosis proportionally to drug dose
[3]. That effect is obtained via calcium receptors on the
osteoclast surface, triggering a cascade of intracellular
transformations, which eventually leads to osteoclast
apoptosis. The combined action of calcium and stron-
tium ranelate on calcium receptors exerts a much stron-
ger effect on osteoclast apoptosis than each individual
factor acting alone.
Akt
Studies on mice [4] have demonstrated strontium rane-
late effects on osteoblast survival prolongation (in-
creased proliferation and reduced apoptosis) to also
depend on the activation of the Akt kinase-related path-
way of changes. Akt kinase plays a certain role in cellu-
lar processes, including glucose metabolism and cell
proliferation and apoptosis.
Prostaglandins (PGE2)
Studies on mice [4] have demonstrated that the effect
of strontium ranelate on the proliferation and reduced
apoptosis of osteoblasts was neutralised by selective
inhibition of cyclooxygenase-2 (COX-2). The results in-
dicated that the positive effect of strontium ranelate on
osteoblasts depends also on how much it influences
PGE2 production.
OPG/RANKL system (osteoprotegerin/ligand of
the receptor nuclear activator of kappa B factor)
A positive effect of strontium ranelate was observed on
the OPG/RANKL ratio, causing an increased secretion
of osteoprotegerin and its more pronounced activity
with a simultaneous reduction of RANKL expression,
leading to suppression of osteoblast-induced osteoclas-
togenesis. A positive effect of strontium ranelate was
found with regards to maturation of human osteoblasts
and differentiation of osteocytes [5].
Insulin-like growth factor
In the course of a six-month therapy with strontium
ranelate at a daily dose of 2.0 g, an increase of the insu-
lin-like growth factor (IGF-1) concentration was ob-
tained [6]. It is assumed that IGF deficit plays a definite
role in the development of post-menopausal osteoporo-
sis and its administration may exert an advantageous
influence on BMD increase.
The most significant clinical studies
on strontium ranelate in the therapy
of osteoporosis
STRATOS study
The Strontium Ranelate for Treatment of Osteoporosis
(STRATOS) study demonstrated that strontium ranelate
increases bone mineral density in the lumbar spine, decreas-
ing the incidence of new spinal fractures. The daily 2.0 g
dose of strontium ranelate was accepted as the most effec-
tive mode of post-menopausal osteoporosis treatment [7].
A randomised, double-blind study with placebo con-
trol was performed over two years in 353 post-meno-
pausal women with, at least, one identified vertebral
fracture in their history and a T-score in the lumbar spine
< –2.4. The enrolled patients received 0.5, 1.0 or 2.0 g of
strontium ranelate daily or a placebo.
Bone mineral density in the lumbar spine demonstrat-
ed a dose-proportional, rising tendency in the strontium
ranelate-treated group vs. the placebo group. The inci-
dence of spinal fractures fell during the second year of
observation. The activity of alkaline phosphatase bone frac-
tion (a bone formation marker) increased after strontium
ranelate treatment and the concentration of NTx (N-ter-
minal cross-linked telopeptide of type-I collagen, a bone
resorption marker) decreased vs. the placebo group.
SOTI study
In the Spinal Osteoporosis Therapeutic Intervention
(SOTI) study, strontium ranelate was demonstrated to
be an agent already effective in spinal fracture preven-
tion after one year of therapy in post-menopausal wom-
en with advanced osteoporosis [8].
A group of 1,649 women (> 50) with post-menopausal
osteoporosis and, at least, one osteoporotic vertebral frac-
ture in their history and lumbar spine BMD £ 0.840 g/cm2
(Hologic) were enrolled into a three-year, randomised,
double-blind and placebo-controlled study. The patients
received strontium ranelate at a daily dose of 2.0 g or
a placebo. They were also supplemented with calcium
(up to 1,000 mg daily according to diet) and vitamin D3
(400–800 IU/d). The study was preceded by a period last-
ing from two weeks to six months (Fracture Internation-
al Run-in for Protelos — FIRST programme), in which
calcium and vitamin D3 deficits measured by serum
25(OH)D3 concentration, were supplemented.
A 41% decrease in the incidence of new spinal frac-
tures was found vs. the placebo group (p < 0.001) and
a 14.4% BMD increase in the lumbar spine vs. the pla-
cebo group. A lower incidence of new fractures was con-
firmed already after one year of treatment (fracture in-
cidence reduction > 49% vs. the placebo group).
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TROPOS study
The Treatment Of Peripheral Osteoporosis (TROPOS)
study demonstrated strontium ranelate to be an agent
that significantly reduced the all-extravertebral fracture
risk during three years of treatment. It significantly de-
creased the risk of hip fractures in patients particularly
endangered by such events (age ≥ 74 years and T-score
£ –3.0) during three years of treatment. It reduced the
number of spinal fractures after the first year of thera-
py, with that effect maintained for the entire three years
of treatment, in patients with and without a vertebral
fracture in their history [9].
A group of 5,091 women aged > 74 years or 70–74 years
with at least one bone fracture risk factor (osteoporotic
fracture during post-menopausal period, stay at a nurs-
ing home, osteoporotic fracture in history of patient’s
mother) and with femoral neck BMD £ 0.600 g/cm2
(Hologic) were enrolled into a five-year, randomised,
double-blind and placebo-controlled study. The patients
received strontium ranelate at a daily dose of 2.0 g or
a placebo. They were also supplemented with calcium
(up to 1,000 mg per day according to diet) and vitamin
D3 (400–800 IU per day). The study was preceded by
a period from two weeks to six months, the FIRST pro-
gramme, in which calcium and vitamin D3 deficits were
supplemented, measured by serum 25(OH)D3 concen-
tration.
After three years of treatment, a 16% decrease was
observed in the incidence of all extravertebral fractures
(p = 0.04). The applied therapy reduced the number of
extravertebral (hip, wrist, pelvic, caudal, costal, sternal,
clavicular and humeral) fractures, osteoporotic in char-
acter, by 19% (p = 0.031). The incidence of proximal
femoral bone fractures decreased by 15%, although this
was statistically insignificant. In the group of women
with the highest fracture risk (age ≥ 74 years and
T-score £ –3.0), the risk of proximal femoral bone frac-
ture decreased by 36% (p = 0.046). The number of new
vertebral fractures, evaluated by X-ray, fell by 39%
(p < 0.001) among all the patients, and by 45% among
the women without vertebral fracture in their history. In
the group of patients treated with strontium ranelate,
a more prominent increase of BMD was observed in the
femoral neck and the total hip vs. the placebo group.
Strontium ranelate was well tolerated in all the above-
mentioned studies, with most symptoms occurring dur-
ing the first three months of drug administration [9].
The efficacy of strontium ranelate
in post-menopausal osteoporosis
This part of the review looks at the efficacy of stron-
tium ranelate in bone fracture prevention, its effects  on
bone and life quality improvement, and on bone min-
eral density and the concentration of bone metabolism
markers.
Bone fracture prevention
The anti-fracture efficacy of strontium ranelate has been
demonstrated in all the skeleton fragments where such
efficacy has also been studied in the cases of other drugs.
Thus, strontium ranelate has been effective in:
— the spine [7, 8]: the longest observation period, re-
garding anti-fracture efficacy within the spine was
eight years [10];
— the hip [9];
— extravertebral skeleton fragments [13].
Number Needed to Treat (NNT) — the number of
subjects who have to be treated to obtain the assumed
effect within a specific period of time for strontium rane-
late to prevent vertebral fractures during a three-year
therapy period is 9.
Number Needed to Treat for strontium ranelate to
prevent hip fractures during a three-year therapy peri-
od is 48 [11].
Following a review of the literature concerning third
phase studies of medical agents with proven anti-frac-
ture efficacy which are available in Europe, the lowest
NNT value was found for strontium ranelate as opposed
to all other drugs [11].
Bone quality improvement
Bone quality was evaluated by an analysis of biopsied
material. Qualitative and quantitative changes, identi-
fied in histomorphometric study, following strontium
ranelate therapy, can be responsible for bone quality
improvement and fracture risk reduction.
A study performed in 133 women with post-meno-
pausal osteoporosis, treated for 1–5 years with stron-
tium ranelate (2.0 g daily) indicates that changes in os-
seous microarchitecture may explain the drug’s anti-
fracture efficacy  demonstrated during osteoporosis
therapy [12].
Significant changes were found in bone microarchi-
tecture, including: higher thickness of cortical bone,
a higher number of osseous trabeculae and smaller spaces
between osseous trabeculae in the patients treated with
strontium ranelate vs. those in the control group. Also,
osteoblast surface was larger after the administration of
strontium ranelate vs. the control group. In the group
of women receiving strontium ranelate, an increased rate
of trabecular bone mineralisation was observed vs. that in
the control group. No cortical bone porosity was found in
the group treated with strontium ranelate.
Another study [13] found that strontium deposited
preferentially in newly formed bone during strontium
ranelate treatment with maintained collagen cross-link-
ing. Bone mineralisation was increased mainly as a re-
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sult of strontium deposition in bones rather than by
changes in calcium content. Bone quality indices were
maintained in women with post-menopausal os-
teoporosis treated with strontium ranelate, combined
with calcium and vitamin B.
The presence of strontium only in the newly formed
bone after a three-year therapy with strontium rane-
late in women with post-menopausal osteoporosis was
also confirmed in another report [14]. No more than
0.5–10 calcium atoms were replaced by strontium in
hydroxyapatite. The proportion of strontium to calci-
um atoms in hydroxyapatites did not exceed 1 in 20,
while neither the thickness nor the length of hydroxya-
patites changed as a result of the applied treatment. No
changes in bone quality were found during the treat-
ment apart from the partial replacement of calcium at-
oms by strontium atoms in newly formed bone.
Life quality improvement
The results of the QUALIOST questionnaire con-
firmed that three-year therapy with strontium ranelate
significantly improved life quality in its emotional and
physical aspects vs. placebo [15]. Back pain remission
was observed in the majority of the patients vs. the pla-
cebo group. Life quality improvement, described in
another report [16], was observed in a group of women
aged > 80 years treated with strontium ranelate.
Effects on bone mineral density
Strontium ranelate increases bone mineral density in
the lumbar spine [7, 8], the femoral neck and in the to-
tal hip [9]. It partially depends on the unspecific effects
of strontium atoms deposited in the newly formed bone
and with an atomic weight > than that of calcium [13].
Effects on the concentration of bone
metabolism markers
Strontium ranelate increases the activity of alkaline
phosphatase bone fraction in serum (bone formation
marker) and, simultaneously, reduces the concentration
of NTx (bone resorption marker) [7].
By contrast, no increase was seen in the concentra-
tion of bone formation markers (the activity of alkaline
phosphatase bone fraction), and there was even a slight
reduction of PINP (N-terminal propeptide of procol-
lagen of type I) in serum after three and six months of
therapy with strontium ranelate, as described in one of
the reports [17].
In whom is strontium ranelate effective in
bone fracture prevention in osteoporosis?
In the rest of this review, the presented information
concerns the effectiveness of strontium ranelate thera-
py in reducing bone fracture risk and  increasing bone
mineral density.
The current FRAX® method, used to evaluate ten-
year bone fracture risk and useful in qualifying patients
to diagnostic examinations and therapy for osteoporo-
sis, was not known at the time of studies on strontium
ranelate (as well as on other drugs). Therefore, patients
were qualified for therapy by the presence of bone frac-
tures (in the spine) and on the basis of specific DXA
examination results. Analysing the obtained results
(very often post hoc), it is possible to determine in which
groups of patients positive therapy effects are to be ex-
pected, and whether the drug efficacy depends on the
patients’ age at therapy onset or on osteoporotic bone
fracture in their history or  base DXA results or base
values of bone metabolism marker concentrations.
The following information draws on post hoc analy-
ses of the above-mentioned main clinical studies (STRA-
TOS, SOTI, TROPOS).
Influence of patients’ age prior to treatment
Strontium ranelate effectively prevents spinal fractures
in post-menopausal women regardless of their age.
Strontium ranelate was found to be the first anti-
osteoporotic agent of long-term efficacy in preventing
vertebral and nonvertebral fractures during five-year
therapy in women aged > 80 years [16]. Vertebral frac-
ture risk was reduced by 31% and nonvertebral frac-
ture risk by 27% in patients aged > 80 years during five
years of treatment [16].
The three-year treatment with strontium ranelate of
1,488 women aged 80–100 decreased the risk for spinal
fractures by 32%, nonvertebral fractures by 31%, and for
all clinically evident fractures (vertebral and extraverte-
bral) by 22% [18]. After one year of treatment, the risk for
spinal fractures decreased by 59%, for nonvertebral frac-
tures by 41%, and for all clinically evident fractures by 37%.
In a group of 353 women aged 50–65 with advanced
post-menopausal osteoporosis (at least one vertebral
fracture in their history), a four-year therapy with stron-
tium ranelate reduced the risk of new vertebral frac-
ture by 35% [19]. In that group, a significant increase in
bone mineral density was achieved, amounting to 15.8%
in the lumbar spine and 7.1% in the femoral neck.
Influence of bone mineral density
prior to treatment
Strontium ranelate effectively prevents spinal fractures
regardless of base bone mineral density values.
Strontium ranelate, administered for five years to
5,091 post-menopausal women with osteoporosis, de-
creased the risk of vertebral fractures by 24% and of
nonvertebral fractures by 15% vs. the placebo group.
The risk of hip fractures in a group of 1,128 women
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(a post hoc analysis in a group of women at high risk of
bone fracture i.e. ≥ 74 years and with lumbar spine and
femoral neck DXA T-score £ –2.4) decreased during five
years of treatment by 43% vs. the placebo group [20].
Strontium ranelate, administered in a group of wom-
en with lumbar spine osteopenia and any femoral neck
DXA score, reduced the risk of spinal fracture in women
with or without vertebral fracture in their history [21].
Effect of bone fracture in history
prior to treatment
An analysis of results from the SOTI and TROPOS pro-
grammes [22], concerning women aged > 74, found that
the anti-fracture efficacy of strontium ranelate in the
spine did not depend on spinal fracture(s) in history
before therapy onset.
Effect of the concentration of bone
metabolism markers prior to treatment
No difference has been demonstrated between the anti-
fracture efficacy of strontium ranelate in the spine vs. the
base values of bone metabolism markers [23]. The three-
year study, in which the activity of alkaline phosphatase
bone fraction (bone formation marker) and the concen-
tration of CTx (C-terminal, cross-linked telopeptide of col-
lagen-I, bone resorption marker) in serum were studied,
concerned women with post-menopausal osteoporosis.
Influence of other factors present
prior to treatment
An analysis of results from the SOTI and TROPOS pro-
grammes [22], concerning women aged > 74, found that
the anti-fracture efficacy of strontium ranelate within
the spine did not depend either on osteoporosis in fam-
ily history or on tobacco smoking.
In whom does strontium ranelate
increase bone mineral density?
Influence of patients’ age prior to treatment
A positive effect of strontium ranelate on bone mineral
density was observed regardless of the age of post-
menopausal women.
In older women, that effect was demonstrated in the
STRATOS [7], SOTI [8] and TROPOS [9] studies.
In women in the early post-menopausal period, that
effect was shown in the PREVention Of early post-
menopausal bone loss by Strontium ranelate (PREVOS)
study [24]. A dose of 1.0 g/day of strontium ranelate was
found to be the smallest effective dose to prevent bone
mass loss in women in the early post-menopausal peri-
od. After two years of treatment, a significant increase
in bone mineral density was obtained in the lumbar
spine and the femoral neck vs. the placebo group.
Which factors give a prognosis of the
anti-fracture efficacy of strontium ranelate?
Identifying the changes observed in the course of treatment
which determine the anti-fracture efficacy of strontium rane-
late is very important. Since the degree to which bone min-
eral density changes during the applied treatment is the
main index of its efficacy, it is important to determine the
degree by which bone fracture risk reduction depends on
bone mineral density. It is also imperative to discover wheth-
er changes in the concentration of bone metabolism mark-
ers give a prognosis of bone fracture risk reduction.
Effects of bone mineral density changes on the
anti-fracture efficacy of strontium ranelate
Changes in bone mineral density may go a long way to
explaining the anti-fracture efficacy of strontium rane-
late in osteoporosis therapy.
Bone mineral density changes in the femoral neck
and the total hip, observed after three years of treat-
ment, were responsible for the reduction of risk of new
spinal fractures by 76% and 74%, respectively [25].
The 1% increase of bone mineral density in the fem-
oral neck after three years of therapy was associated
with a decreased risk of new vertebral fractures of 3%.
The 1% increase of bone mineral density in the total
hip after three years of therapy was associated with
a decreased risk of vertebral fracture by 2%.
The increase of bone mineral density in the femoral
neck after one year of therapy was significantly associ-
ated with a decreased risk of vertebral fractures after
three years of therapy.
Changes in bone mineral density in the lumbar spine
after three years of treatment were not significantly as-
sociated with a decreased risk of new vertebral fractures.
Changes in bone mineral density in all the skeleton
fragments were not connected with a decreased risk of
nonvertebral fractures.
Another report [10] found that bone mineral densi-
ty changes in the total hip negatively correlated with
the risk of vertebral fractures during the last three years
of an eight-year therapy with strontium ranelate. The
increase of bone mineral density in the total hip during
the eight-year therapy assumed reduction of the risk of
new vertebral fractures in post-menopausal osteoporo-
sis. A 1% increase of bone mineral density in the total
hip reduced the risk of vertebral fracture by 5%.
Bone metabolism changes evaluated by changes
in the concentration of bone metabolism markers
Changes in the concentrations of all the studied bone
metabolism markers, observed after three months of ther-
apy, did not initially assume any efficacy of the three-
year anti-fracture therapy with strontium ranelate [26].
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The concentration changes of bone metabolism markers
explained less than 8% of bone mineral density changes.
Changes in the concentration of pro-collagen type I
C-terminal peptide (PICP) and in alkaline phosphatase
bone fraction activity after three months of therapy as-
sumed changes in lumbar spine and femoral neck bone
mineral density. Changes in CTx and PICP concentra-
tions and in the activity of alkaline phosphatase bone
fraction assumed total hip BMD changes.
Cost-effectiveness of post-menopausal
osteoporosis therapy with strontium
ranelate
Studies into the cost-effectiveness of strontium ranelate
administration in the therapy of post-menopausal os-
teoporosis have been performed in Belgium [27, 28] and
the UK [29], estimating the costs in terms of a quality-
adjusted life year (QALY).
In Belgium, cost-effectiveness was evaluated of
three-year therapy with strontium ranelate, applied for
women aged 75 and 80 with osteoporosis identified by
DXA, or with a spinal fracture in their history. The drug
turned out to be cost-effective in the group of women
aged 75 with densitometric criteria for osteoporosis di-
agnosis and for the women aged 80 with a vertebral
fracture in their history vs. untreated women or those
treated with risedronate. The therapy was evaluated as
cost-effective also in a five-year perspective.
In the UK, therapy with strontium ranelate was es-
timated as cost-effective vs. no therapy at all in a group
of women aged ≥ 65 with a bone fracture in their histo-
ry of an osteoporotic character, confirmed by DXA re-
sults: T-score £ –2.5, and in a group of women of the
same age with a bone fracture in their history with no
known DXA results. With the declared readiness to in-
cur annual costs for QALY in the amount of 30 thou-
sand pond sterling, the borderline ten-year risk of bone
fracture, estimated by the FRAX® method, was 16.9%,
increasing to 25.7% with annual spending for QALY at
the level of 20 thousand pond sterling [29].
No Polish data is available concerning the cost-ef-
fectiveness of strontium ranelate administration in the
therapy of post-menopausal osteoporosis.
A comparison of strontium ranelate with
other agents of proven anti-fracture activity
No reports are available which evaluate the anti-frac-
ture efficacy of strontium ranelate in a head-to-head
study vs. that of other agents.
Alendronate
During one-year therapy with strontium ranelate, a sig-
nificantly higher improvement in trabecular bone and
cortical tibial bone microstructures was obtained follow-
ing high resolution CT evaluations vs. that after alen-
dronate therapy (weekly dose of 70 mg) [30].
A similar incidence of venous thromboembolic epi-
sodes has been seen in both therapeutic groups and in the
placebo group [31]. The incidence of thromboembolic ep-
isodes in the UK’s population of female patients treated
with strontium ranelate, was similar to the incidence ob-
served in third and fourth phase studies of the drug.
Teriparatide
No significant differences have been found between
either drug, regarding its effect on the histomorpho-
metric parameters of bone formation and resorption,
while the anti-fracture activity of strontium ranelate was
explained by other than anabolic effects [17]. In both ther-
apies, a similar effect was obtained on trabecular bone
mineralisation surface changes. In the teriparatide-ad-
ministered group, a statistically significant increase was
obtained in the values of bone formation markers (PINP
and alkaline phosphatase bone fraction). In the stron-
tium ranelate- treated group, a statistically significant re-
duction was observed in the concentrations of bone for-
mation (PINP) and bone resorption (CTx) markers.
Strontium ranelate applications, following
the administration of other agents with
anti-fracture efficacy
After bisphosphonate treatment
Strontium ranelate administration may be considered
as a continuation of long-term therapy with bisphos-
phonates [32]. A histomorphometric bone analysis, per-
formed after six-month therapy, revealed increased os-
teoid surface and higher strontium content in the bone.
Following 12 months of treatment, increased bone vol-
umes were found, with thicker bone trabeculae and
a higher strontium content in the bone. There were also
a higher number of osteoblasts with increased osteoid
surface and volume. Low bone resorption was observed
with a small number of osteoclasts.
After teriparatide treatment
In the course of a 12-month therapy with strontium
ranelate, administered to women previously treated
with teriparatide for 18 months, a further increase in
lumbar spine BMD was obtained [33].
Drug information
The following information summarises the publications
quoted in this review, as well as the characteristics of
the medicinal product.
The drug is available in granulate form (2.0 g sa-
chets), ready to prepare oral suspension.
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The drug is absorbed in the digestive tract. With
a single dose of the drug > 1.0 g, the absorption pro-
cess is mainly passive in character. The bioavailability
of strontium ranelate is 27% and it is excreted mainly
through the kidneys.
Indications
— Osteoporosis treatment in women after menopause
to reduce the risk of vertebral fractures.
Contraindications
— Oversensitivity to the drug
— Renal insufficiency (creatinine clearance < 30 ml/min)
Precautions
— Carefully apply to subjects with an increased risk of
venous thromboembolic disease (current and in his-
tory)
— Do not use during pregnancy or breast-feeding
— Do not combine the drug with tetracyclines or
chinolones
— Do not administer the drug to bedridden or post-
operative patients
Indications to withdraw drug administration
The indications for drug withdrawal include the occur-
rence of allergic reactions. These are: oedema of the face,
tongue or pharynx, impaired breathing or swallowing,
skin eruption.
In cases of oversensitivity reaction, the drug should
not be prescribed in future.
Dosage in the therapy of post-menopausal
osteoporosis
The drug is administered in oral doses (a 2.0 g sachet
daily). Bioavailability is reduced by 60–70% with combined
calcium administration and during meals, therefore:
— the drug should be administered at least two hours
after a meal, optimally in the evening after dinner;
— at least a two-hour interval is recommended between
strontium ranelate and calcium
No dose modification is required in case of liver dis-
eases.
Neither vitamin D nor calcium administration is
obligatory; they are, however, recommended in cases
of their deficit. Adverse effects which may occur in the
course of treatment are presented in Table I.
Adverse effects occur most frequently during the
first three months of therapy.
Also described: vomiting, abdominal pains, irrita-
tions of oral mucous membrane, bone, joint and mus-
cle pains, allergic reactions, pruritus, urticaria or vaso-
motor oedema.
Single cases of the Drug Rash with Eosinophilia and
Systemic Symptoms (DRESS) syndrome have been de-
scribed [34, 35]. This is a rare oversensitivity reaction,
usually occurring three to six weeks from therapy on-
set, and characterised by fever, rash, eosinophilia and
generalised symptoms (e.g. hepatitis or nephritis) [35].
The occurrence of DRESS syndrome is an indication for
definitive discontinuation of therapy with strontium
ranelate.
Single cases have been described of severe, desqua-
mative dermatitis after treatment with strontium rane-
late [36].
Analysis performed in the UK between 2004 and
2008 concerning venous thromboembolic episodes dur-
ing the first year of therapy with strontium ranelate
found a similar prevalence of those episodes in an age-
matched group and in a group on anti-fracture medi-
cations for post-menopausal osteoporosis [37]. The prev-
alence of thromboembolic episodes, recorded in the
population of patients treated with strontium ranelate
was similar to that observed in third and fourth phase
trials of the drug.
Summary
1. Strontium ranelate is a first-line medical agent in the
therapy of post-menopausal osteoporosis.
2. The mechanism of action makes the drug distinct
from other medical agents, as it simultaneously stim-
ulates bone formation and inhibits bone resorption.
The activity of the drug depends on various mecha-
nisms, including the activation of calcium receptors,
localised on osteoblasts and osteoclasts and on the
effects on the OPG/RANKL system.
3. The drug is effective in preventing bone and hip frac-
tures and nonvertebral fractures. The anti-fracture
efficacy within the spine does not depend on the
age of the  patient nor on base bone mineral density
Table I. Adverse effects which may occur in the course of
treatment
Tabela I. Działania niepożądane mogące pojawić się w czasie
leczenia
Most frequent Less common Rare
Nausea Venous Convulsive
thrombosis  seizures
Diarrhoea Fainting
Loose stool Memory loss
Headache Consciousness
disturbances
Dermatitis
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values nor on the concentrations of bone metabo-
lism markers. The anti-fracture efficacy in the hip
concerns women with post-menopausal osteoporo-
sis and with an increased risk of bone fracture.
4. It also decreases the concentration of bone resorp-
tion markers, while increasing the concentration of
bone formation markers.
5. The very broad range of conditions in which the
drug demonstrates anti-fracture efficacy makes it
a very attractive proposal for pharmacological man-
agement in post-menopausal osteoporosis.
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